Guidelines for frequency and duration of JIA-U screening are based on existing clinical risk factors of gender, JIA subtype, age of JIA onset, and anti-nuclear antibody (ANA) and HLA-B27 status. The gene discussed is BTG3; the disease is juvenile idiopathic arthritis.